Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval
Syndax Pharmaceuticals' drug Revuforj, a menin inhibitor, received FDA approval for treating acute leukemia with KMT2A translocation, offering a new treatment option for patients with poor prognoses. The drug, priced at $39,500/month, showed promising results in a Phase 1/2 study, with 21.2% achieving complete remission. Revuforj carries a black box warning for differentiation syndrome risk.
AI Can Transform Drug Development, New ITIF Report Finds
AI can halve drug development times by boosting efficiency across the entire pipeline, from discovery to manufacturing, according to ITIF. AI tools accelerate drug target identification, optimize clinical trial designs, and enhance manufacturing efficiency, making therapies more accessible. ITIF recommends supportive policies for AI's full potential, including privacy-enhancing data sharing, public research funding, risk-based regulatory standards, and workforce training.
The PFA race is heating up. Here's where the market stands after J&J's approval.
Competition in the pulsed field ablation (PFA) market intensifies with Johnson & Johnson's Varipulse, Boston Scientific's Farapulse Nav, and Medtronic's Affera. These devices treat atrial fibrillation (AFib) with integrated mapping, offering faster and safer procedures compared to traditional methods. PFA is rapidly becoming the standard of care, with Boston Scientific and Medtronic seeing strong adoption. Abbott trails with its Volt device expected to file for FDA approval next year.
J&J: positive CHMP opinion for Lazcluze in lung cancer
J&J's Janssen-Cilag receives CHMP recommendation for Lazcluze + Rybrevant in advanced NSCLC with EGFR mutations, based on a phase 3 study showing a 30% reduction in progression or death risk compared to osimertinib.
Pulmonary Vein Isolation With Optimized Linear Ablation for Persistent AF
Linear ablation combined with ethanol infusion via the vein of Marshall (EIVOM) significantly improves freedom from atrial arrhythmia recurrence without antiarrhythmic drugs (70.7% vs 61.5%; hazard ratio, 0.73) in patients with persistent atrial fibrillation (AF) undergoing first-time ablation, according to a randomized clinical trial involving 498 patients.
Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC
EMA’s CHMP recommended marketing authorization for lazertinib with amivantamab in frontline treatment of advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. MARIPOSA study results showed a median PFS of 23.7 months with the combination vs 16.6 months with osimertinib, reducing risk of disease progression by 30%. Longer follow-up revealed a trend of OS benefit, with 61% survival at 3 years in the combination arm vs 53% in the osimertinib arm.
Watchman FLX demonstrates superiority to anticoagulants in study
Boston Scientific announced positive three-year results for its Watchman FLX device in a clinical trial, demonstrating superiority to oral anticoagulation for stroke risk reduction in non-valvular atrial fibrillation patients post-cardiac ablation. The OPTION trial met primary safety and efficacy endpoints, with Watchman FLX showing non-inferiority and potential to expand its indication as a frontline therapy.
Masimo Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Masimo Corporation entered into an employment agreement with Michelle Brennan, appointed interim CEO on September 24, 2024, effective until March 24, 2025, or until a new CEO is appointed. The agreement includes an annual base salary of $1,042,000, a discretionary bonus of $621,250, and an equity award of 8,916 restricted stock units (RSUs) that vest on the same conditions. Brennan, a former senior executive at Johnson & Johnson, is also entitled to participate in company benefits plans.
CHMP Recommends Approval Of Lazcluze + Rybrevant In EU For EGFR-mutated Advanced NSCLC
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Medicines Agency's CHMP recommended approval of Lazcluze with Rybrevant for EGFR-mutated advanced NSCLC. The CHMP also recommended a Type II indication extension for amivantamab in the same combination. These recommendations are supported by the Phase III MARIPOSA study, which showed a 30% reduction in disease progression or death compared to Tagrisso, with a median progression-free survival of 23.7 months versus 16.6 months for Tagrisso.
CHMP recommends RYBREVANT in combination with LAZCLUZE for the first-line treatment
Janssen-Cilag International NV announced CHMP's recommendation for LAZCLUZE (lazertinib) and RYBREVANT (amivantamab) for first-line treatment of advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. The combination could establish a new standard of care, potentially delaying disease progression and improving outcomes.
© Copyright 2024. All Rights Reserved by MedPath